Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Slides:



Advertisements
Similar presentations
Figure 1 Proposed risk stratification for patients with NAFLD
Advertisements

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Cardiol. doi: /nrcardio
Figure 4 Activation of clopidogrel via cytochrome P450
Figure 5 Therapeutic paradigms for interfering with the brain–gut axis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 7 Treatment algorithm for perianal fistulizing disease
Figure 6 Injection of mesenchymal stem cells in perianal fistulas
Figure 1 Patients cured of HCV infection
Figure 2 A stage-based approach to the treatment of NAFLD
Figure 7 Management algorithm for patients with ACLF
Figure 1 Gut microorganisms at the intersection of several diseases
Figure 5 Lipid droplet consumption
Figure 4 Simple perianal fistula
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 The microbiome–gut–brain axis
Figure 3 The T-cell cytokine tree in IBD
Figure 1 Organs involved in coeliac-disease-associated autoimmunity
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process
Figure 3 Algorithm from working group describing
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Effect of PPIs on gastric physiology
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 4 Giant lipid droplet formation
Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.
Figure 6 Combination therapy for HCC
Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.
Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.
Figure 1 Definition and concept of ACLF
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 5 Complex perianal fistula
Figure 2 Switching of biologic agents and biosimilars
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
to the liver and promote patient-derived xenograft tumour growth
Figure 7 Example colonic high-resolution manometry
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Environmental factors contributing to IBD pathogenesis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Median coverage and distribution by
in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)
Figure 5 Chrononutrition in the liver
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Possible therapeutic targets to decrease hepatic steatosis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Strategies to improve liver regeneration
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
with broad-spectrum antibiotics
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Assessment of colonic transit time with radiopaque markers
Figure 5 Systems biological model of IBS
Figure 4 Local species pools that contribute to the
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Lifelong influences on the gut microbiome from
Figure 1 NAFLD pathogenesis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Presentation transcript:

Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.139 Figure 1 Balance of risks and benefits of medical versus surgical therapy in Crohn's disease Figure 1 | Balance of risks and benefits of medical versus surgical therapy in Crohn's disease. Risk stratification can be divided into four tiers and, in deciding on either a medical or a surgical approach for patients with Crohn's disease, these risks should be carefully evaluated and balanced with the advantages and disadvantages of medical and surgical therapy. Shen, B. (2017) Step‑up vs top-down therapy for Crohn’s disease: medicine vs surgery Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.139